CPU socket

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024

Retrieved on: 
Saturday, March 9, 2024
Pustulosis palmaris et plantaris, Psoriasis, CPU socket, Aes, Headache, Diarrhea, Amgen, Pain, Pediatrics, DLQI, Skin, Nausea, Vomiting, Queen's University, AMGN, AAD, Safety, University, FRCPC, University of Alberta, PASI, Dermatology Life Quality Index, Patient, PST, Scalp, Ageing, Abdominal pain, Poster, American Academy, Pharmaceutical industry

THOUSAND OAKS, Calif., March 9, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new, 52-week results from the Phase 3 SPROUT study examining the use of Otezla® (apremilast) in children and adolescents aged 6 to 17 years with moderate to severe plaque psoriasis. These data, along with findings from a Phase 3 late-breaking study on Otezla in palmoplantar pustulosis, will be presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12 in San Diego.                                     

Key Points: 
  • These data, along with findings from a Phase 3 late-breaking study on Otezla in palmoplantar pustulosis, will be presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting, March 8-12 in San Diego.
  • "These data reflect Amgen's commitment to exploring new ways to treat inflammatory skin disease," said Ponda Motsepe-Ditshego, vice president, Global Medical, at Amgen.
  • Continued Otezla use resulted in sustained improvements in psoriasis severity and skin involvement in patients for up to one year.
  • Findings will be presented as a late-breaking oral presentation on Saturday, March 9 at 9:20 a.m. PST.

Human medicines European public assessment report (EPAR): Sotyktu, deucravacitinib, Date of authorisation: 24/03/2023, Revision: 1, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Janus, Patient, Medical Subject Headings, Marketing, Cytokine, Protein, Human, INN, Infection, ATC, Pharyngitis, International, Nose, Language, Mouth, CPU socket, Inflammation, JAK, European Medicines Agency, Lower respiratory tract infection, PASI, Tablet, Select, Cell, Diagnosis, Janus kinase, TYK2, Anatomy, IIA, Skin, Medical device

Human medicines European public assessment report (EPAR): Sotyktu, deucravacitinib, Date of authorisation: 24/03/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Sotyktu, deucravacitinib, Date of authorisation: 24/03/2023, Revision: 1, Status: Authorised

Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy and Consistent Safety for up to Three Years in Moderate-to-Severe Plaque Psoriasis

Retrieved on: 
Wednesday, October 11, 2023
Biotechnology, Pharmaceutical, Finance, Oncology, Health, FDA, Professional Services, Clinical Trials, Congress, Bristol Myers Squibb, NYSE, PASI, Coronary thrombosis, Journal of the European Academy of Dermatology and Venereology, Abstract, Research, Circulatory system, Aes, AE, Risk, Bolivian National Congress, 1985–1989, Malignancy, Death, University, Week, MPH, Safety, Psoriasis, Conditional sentence, Psoriasis Area and Severity Index, Shingles, Plaque, CPU socket, Head, PSO, LTE, BMY, Patient, Pharmaceutical industry, Dermatology, MD, Venereology, Immunology, Deucravacitinib, TYK2

Bristol Myers Squibb (NYSE:BMY) today announced new three-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis.

Key Points: 
  • Bristol Myers Squibb (NYSE:BMY) today announced new three-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis.
  • Sotyktu demonstrated a consistent safety profile with no increases in the rates of adverse events (AEs) or serious AEs over time, and no emergence of any new safety signals.
  • The efficacy analysis assessed 513 patients who received continuous Sotyktu treatment from Day 1 in the pivotal POETYK PSO-1 and POETYK PSO-2 trials and transitioned to the LTE trial.
  • “These new data validate the potential of Sotyktu to provide long-term, clinically relevant improvement for individuals living with moderate-to-severe plaque psoriasis.”
    Bristol Myers Squibb thanks the patients and investigators involved in the POETYK PSO clinical trial program.

Bristol Myers Squibb Launches Clear Understanding Campaign to Reveal the Plain Truth About Living with Moderate to Severe Plaque Psoriasis

Retrieved on: 
Tuesday, August 8, 2023
Biotechnology, Pharmaceutical, Health, Other Health, Injection, Bristol Myers Squibb, Psoriasis Area and Severity Index, Aphthous stomatitis, Mouth, Allergy, Face, Friends, Week, Chronic pain, Infection, CPU socket, Clear, American Academy, Acne, Multimedia, Inflammation, National Psoriasis Foundation, Psoriasis, BMY, Yale School of Medicine, Hyperkinesia, Light, Dermatology, Eyelid, Patient, AAD, Sinusitis, Immune system, Conditional sentence, TYK2, PASI, NPF, Glycine mollis, FDA, Rash, Family, Tongue, NYSE, Skin, Disease, Pharmaceutical industry, Deucravacitinib, Chronicon

View the full release here: https://www.businesswire.com/news/home/20230804756518/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230804756518/en/
    Nitika, living with moderate to severe plaque psoriasis.
  • (Photo: Bristol Myers Squibb)
    “I was young when I was diagnosed with moderate to severe plaque psoriasis, and it felt like my whole life revolved around my condition.
  • “This insight drove us to launch the Clear Understanding campaign to recognize those concessions and encourage people living with moderate to severe plaque psoriasis to talk to their dermatologist about available treatment options."
  • In two studies of moderate to severe plaque psoriasis, Sotyktu was compared to placebo and Otezla® (apremilast).

Micro Center Unveils Exclusive Launch of AMD Ryzen™ 5 5600X3D Processor, Delivering Incredible Gaming Performance at an Unbeatable Price

Retrieved on: 
Friday, June 30, 2023
Hertz, TDP, Life, Electronics, AMD, 3D, NVME, Micro Center, DDR4, CPU socket, RAM, Architecture, Ryzen, GPU, Micro, ASUS, GB, Video game

HILLIARD , Ohio, June 30, 2023 /PRNewswire-PRWeb/ -- Micro Center (microcenter.com), a premier destination for computer hardware and electronics, is thrilled to announce the exclusive launch of the AMD Ryzen™ 5 5600X3D processor. This limited-edition processor offers outstanding price-to-performance value, allowing gamers to enhance their gaming experiences without compromising their budget. Available exclusively at Micro Center starting July 7th, 2023, the AMD Ryzen™ 5 5600X3D processor delivers exceptional power and responsiveness, setting a new standard for gaming performance at an unbeatable price.

Key Points: 
  • HILLIARD , Ohio, June 30, 2023 /PRNewswire-PRWeb/ -- Micro Center ( microcenter.com ), a premier destination for computer hardware and electronics, is thrilled to announce the exclusive launch of the AMD Ryzen™ 5 5600X3D processor.
  • Available exclusively at Micro Center starting July 7th, 2023, the AMD Ryzen™ 5 5600X3D processor delivers exceptional power and responsiveness, setting a new standard for gaming performance at an unbeatable price.
  • "At Micro Center, we are thrilled to partner with AMD and introduce the limited-edition AMD Ryzen 5 5600X3D processor to our valued customers," said Warren Beneson, Chief Merchandising Officer at Micro Center.
  • Priced at an unbeatable $229.99, the limited-edition AMD Ryzen™ 5 5600X3D processor provides exceptional value for gamers seeking uncompromising performance.

Bristol Myers Squibb Data at the EADV 30th Anniversary Congress Highlight the Growing Body of Evidence on Deucravacitinib and Scientific Advancements for Patients with Serious Dermatologic Diseases

Retrieved on: 
Thursday, September 30, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Janus, CEST, PASI, Week, Fibrosis, Congress, Journal of the European Academy of Dermatology and Venereology, JAK, CPU socket, Multimedia, Prior, TYK2, Apremilast, Â, Psoriasis Area and Severity Index, Dry, Itch, Psoriasis, Gaps, Immunology, Bristol Myers Squibb, Salford Royal NHS Foundation Trust, Pharmacology, Late, Disease, Comparative effectiveness research, Atopic dermatitis, Risk, Science, Research, Alopecia areata, PSSD, University, Jeff Flake, Neutrophil, BMY, NYSE, University of Manchester, Pharmaceutical industry, Deucravacitinib, the Phase 3 POETYK PSO-1 and POETYK PSO-2 Studies, Psoriasis, Bristol Myers Squibb, DEUCRAVACITINIB, THE PHASE 3 POETYK PSO-1 AND POETYK PSO-2 STUDIES, PSORIASIS, BRISTOL MYERS SQUIBB

Bristol Myers Squibb (NYSE: BMY) today announced that data from 19 company-sponsored scientific presentations are being shared at the European Academy of Dermatology and Venereology (EADV) 30th Anniversary Congress taking place September 29 October 2, 2021.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that data from 19 company-sponsored scientific presentations are being shared at the European Academy of Dermatology and Venereology (EADV) 30th Anniversary Congress taking place September 29 October 2, 2021.
  • These data (Presentation #2857) are being presented today during the Late Breaking News Session from 3:45 4:45 p.m. CEST.
  • Bristol Myers Squibb-sponsored abstracts presented at EADVs 30th Anniversary Congress can be found below and accessed online here .
  • Visit this page on BMS.com for more information on Bristol Myers Squibbs scientific approach and resources on dermatologic immune-mediated diseases.

AMD Announce World’s First 64-Core PRO Workstation, the Lenovo™ ThinkStation™ P620, the Pinnacle of Performance for Modern Professionals

Retrieved on: 
Tuesday, July 14, 2020
Computer architecture, Advanced Micro Devices, Computers, Zen, Athlon, Ryzen, CPU socket, AMD 10h

For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ:AMD) website , blog , Facebook and Twitter pages.

Key Points: 
  • For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ:AMD) website , blog , Facebook and Twitter pages.
  • 5 Full system memory encryption is included with AMD Memory Guard in AMD Ryzen PRO, AMD Ryzen Threadripper Pro, and AMD Athlon PRO processors.
  • CPP-14
    9 Based on AMD internal analysis June 1, 2020, comparing the PCIe specifications of AMD Ryzen Threadripper PRO to Intel Xeon Platinum 8280.
  • CPP-10
    10 Based on AMD internal analysis June 1, 2020, comparing the PCIe specifications of AMD Ryzen Threadripper PRO to Intel Xeon Platinum 8280.

AMD Offers Enthusiasts More Choice Than Ever Before with New Ryzen™ 3000XT Processors

Retrieved on: 
Tuesday, June 16, 2020
Computer architecture, Advanced Micro Devices, Computers, Zen 2, Zen, Ryzen, CPU socket, Cool'n'Quiet

The AMD Ryzen 9 3900XT, AMD Ryzen 7 3800XT and Ryzen 5 3600XT processors feature tailored specifications engineered for enthusiasts who regularly choose aftermarket cooling for the highest possible performance.

Key Points: 
  • The AMD Ryzen 9 3900XT, AMD Ryzen 7 3800XT and Ryzen 5 3600XT processors feature tailored specifications engineered for enthusiasts who regularly choose aftermarket cooling for the highest possible performance.
  • These AMD 500 Series motherboards including the new A520 provide essential performance for 3rd Gen AMD Ryzen processors and beyond.
  • The AMD Ryzen 3000XT Series processors also come with unbeatable platform support, compatible with all motherboards equipped with a Ryzen 3000-ready BIOS, including day one support on the entire 500 series chipset families.
  • AMD Ryzen 5 3600XT, AMD Ryzen 7 3800XT and AMD Ryzen 9 3900XT processors are expected to be available from top retailers and etailers worldwide starting July 7, 2020.

Patriot Expands its Viper 4 Series DDR 4 Computer Memory and Adds 3rd Gen AMD Ryzen™ and AMD X570 Chipset Support

Retrieved on: 
Wednesday, July 10, 2019
Computer architecture, Computers, Computing, Ryzen, Advanced Micro Devices, Zen, DDR4 SDRAM, Overclocking, Socket AM4, CPU socket

The Patriot Viper 4 DDR4 Blackout series is designed to be a PC-Build-friendly with a potential for overclocking and more extensive compatibility across various Intel and AMD platforms.

Key Points: 
  • The Patriot Viper 4 DDR4 Blackout series is designed to be a PC-Build-friendly with a potential for overclocking and more extensive compatibility across various Intel and AMD platforms.
  • The Patriot Viper 4 Blackout series is available in frequencies of 3000MHz up to 4000MHz and is fully compatible with the latest 3rd Gen AMD Ryzen Desktop Processors and AMD X570 motherboards.
  • "Patriot Viper 4 Blackout series DDR4 computer memory is positioned to offer exceptional performance on the latest 3rd Gen AMD Ryzen Desktop Processors and AM4 platform.
  • Besides, the Viper 4 Blackout series DDR4 computer memory built with best-quality components on a 10-layer black PCB to guarantee excellent signal integrity for ultra-stability.